Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. METHODS: We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis. RESULTS: The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained. CONCLUSIONS: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the safety and efficacy profiles for SC trastuzumab in combination with IV pertuzumab and docetaxel as a first-line treatment for patients with HER2-positive MBC in the MetaPHER study (NCT02402712) was found to be consistent with those observed for IV trastuzumab in combination with IV pertuzumab and docetaxel in the CLEOPATRA study (NCT00567190) [21, 35–38].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Self-citationSmith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Self-citationvon Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Self-citation
Cited by
Breast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Harbeck, N., & Gnant, M. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,280
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Self-citationAdjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703643 · Cited by 1,411
Self-citationChemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery
Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061578 · Cited by 1,241
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,175
Self-citationMosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,186
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Targeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
Self-citationLoibl, S., & Gianni, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32417-5 · Cited by 1,116
Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., Castro, G., Untch, M., Smith, I., Gianni, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32616-2 · Cited by 1,035
Self-citationSwain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30863-0 · Cited by 922
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S.-A., Pedrini, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00163-7 · Cited by 880
Self-citationBreast Cancer Immunotherapy: Facts and Hopes
Emens, L. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 863
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818
“84) No improvement 4 [91-94]”
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Self-citationAwada, A., Colomer, R., Inoue, K., Bondarenko, I., Badwe, R. A., Demetriou, G., Lee, S.-C., Mehta, A. O., Kim, S.-B., Bachelot, T., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0237 · Cited by 305
Self-citationNext generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Hurvitz, S. A., Hegg, R., Chung, W.-P., Im, S.-A., Jacot, W., Ganju, V., Chiu, J. W. Y., Xu, B., Hamilton, E., Madhusudan, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02420-5 · Cited by 687
Self-citationDiéras, V., Miles, D., Verma, S., Pegram, M., Welslau, M., Baselga, J., Krop, I. E., Blackwell, K., Hoersch, S., Xu, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30312-1 · Cited by 667
Self-citationCardiovascular Toxic Effects of Targeted Cancer Therapies
Moslehi, J. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1100265 · Cited by 635
Palmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642
ESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641
Clinical Diagnosis and Management of Breast Cancer
McDonald, E. S., Clark, A. S., Tchou, J., Zhang, P., & Freedman, G. M. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.157834 · Cited by 613
Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A., & Aggarwal, A. (2017) · BMJ · doi:10.1136/bmj.j4530 · Cited by 599
Differences in Breast Cancer Survival by Molecular Subtypes in the United States
Howlader, N., Cronin, K. A., Kurian, A. W., & Andridge, R. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0627 · Cited by 598
Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00147 · Cited by 604
Self-citationPeptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
Metastatic and triple-negative breast cancer: challenges and treatment options
Al-Mahmood, S., Sapiezynski, J., Garbuzenko, O. B., & Minko, T. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0551-3 · Cited by 524
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Implementing Genome-Driven Oncology
Hyman, D. M., Taylor, B. S., & Baselga, J. (2017) · Cell · doi:10.1016/j.cell.2016.12.015 · Cited by 503
Self-citationTabernero, J., Hoff, P. M., Shen, L., Ohtsu, A., Shah, M. A., Cheng, K., Song, C., Wu, H., Eng-Wong, J., Kim, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30481-9 · Cited by 490
Drug Combinations in Breast Cancer Therapy
Fisusi, F. A., & Akala, E. O. (2019) · Pharmaceutical Nanotechnology · doi:10.2174/2211738507666190122111224 · Cited by 449
Brain malignancies: Glioblastoma and brain metastases
Lah, T. T., Novak, M., & Breznik, B. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.010 · Cited by 438
Javle, M., Borad, M. J., Azad, N. S., Kurzrock, R., Abou-Alfa, G. K., George, B., Hainsworth, J., Meric-Bernstam, F., Swanton, C., Sweeney, C. J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00336-3 · Cited by 425
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Nicolini, A., Ferrari, P., & Duffy, M. J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.010 · Cited by 424
Perez, E. A., Barrios, C., Eiermann, W., Toi, M., Im, Y.-H., Conte, P., Martin, M., Pienkowski, T., Pivot, X., Burris, H. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4887 · Cited by 420
Breast Cancer Metastasis: Mechanisms and Therapeutic Implications
Park, M., Kim, D., Ko, S., Kim, A., Mo, K., & Yoon, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126806 · Cited by 406
Mosele, F., Deluche, E., Lusque, A., Le Bescond, L., Filleron, T., Pradat, Y., Ducoulombier, A., Pistilli, B., Bachelot, T., Viret, F., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02478-2 · Cited by 399
Untch, M., Jackisch, C., Schneeweiss, A., Conrad, B., Aktas, B., Denkert, C., Eidtmann, H., Wiebringhaus, H., Kümmel, S., Hilfrich, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00542-2 · Cited by 414
Xu, B., Yan, M., Ma, F., Hu, X., Feng, J., Ouyang, Q., Tong, Z., Li, H., Zhang, Q., Sun, T., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30702-6 · Cited by 402
Butti, R., Das, S., Gunasekaran, V. P., Yadav, A. S., Kumar, D., & Kundu, G. C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0797-x · Cited by 390
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Marchiò, C., Annaratone, L., Marques, A., Casorzo, L., Berrino, E., & Sapino, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.016 · Cited by 377
Piccart-Gebhart, M., Holmes, E., Baselga, J., de Azambuja, E., Dueck, A. C., Viale, G., Zujewski, J. A., Goldhirsch, A., Armour, A., Pritchard, K. I., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1797 · Cited by 371
Self-citationTargeted therapies in breast cancer: New challenges to fight against resistance
Masoud, V., & Pagès, G. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i2.120 · Cited by 357
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Pernas, S., & Tolaney, S. M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833519 · Cited by 348
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
To, C., Jang, J., Chen, T., Park, E., Mushajiang, M., De Clercq, D. J. H., Xu, M., Wang, S., Cameron, M. D., Heppner, D. E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0903 · Cited by 330
Ma, F., Ouyang, Q., Li, W., Jiang, Z., Tong, Z., Liu, Y., Li, H., Yu, S., Feng, J., Wang, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00108 · Cited by 334
Breast Cancer Survivorship, Quality of Life, and Late Toxicities
Nardin, S., Mora, E., Varughese, F. M., D'Avanzo, F., Vachanaram, A. R., Rossi, V., Saggia, C., Rubinelli, S., & Gennari, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00864 · Cited by 330
Priceman, S. J., Tilakawardane, D., Jeang, B., Aguilar, B., Murad, J. P., Park, A. K., Chang, W.-C., Ostberg, J. R., Neman, J., Jandial, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2041 · Cited by 327
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Mazières, J., Barlesi, F., Filleron, T., Besse, B., Monnet, I., Beau-Faller, M., Peters, S., Dansin, E., Früh, M., Pless, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv573 · Cited by 325
Primary and metastatic peritoneal surface malignancies
Cortés-Guiral, D., Hübner, M., Alyami, M., Bhatt, A., Ceelen, W., Glehen, O., Lordick, F., Ramsay, R., Sgarbura, O., Van Der Speeten, K., et al. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00326-6 · Cited by 308
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, P. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0067 · Cited by 294
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E., & de Groot, D. J. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.006 · Cited by 292
Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists
Johnson, K. S., Conant, E. F., & Soo, M. S. (2021) · Journal of Breast Imaging · doi:10.1093/jbi/wbaa110 · Cited by 280
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 283
Personalized Medicine: Recent Progress in Cancer Therapy
Gambardella, V., Tarazona, N., Cejalvo, J. M., Lombardi, P., Huerta, M., Roselló, S., Fleitas, T., Roda, D., & Cervantes, A. (2020) · Cancers · doi:10.3390/cancers12041009 · Cited by 282
Shachar, S. S., Deal, A. M., Weinberg, M., Nyrop, K. A., Williams, G. R., Nishijima, T. F., Benbow, J. M., & Muss, H. B. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0940 · Cited by 288
Towards personalized treatment for early stage HER2-positive breast cancer
Goutsouliak, K., Veeraraghavan, J., Sethunath, V., De Angelis, C., Osborne, C. K., Rimawi, M. F., & Schiff, R. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0299-9 · Cited by 287
The Role of Natural Products as Sources of Therapeutic Agents for Innovative Drug Discovery
Dzobo, K. (2022) · Comprehensive Pharmacology · doi:10.1016/b978-0-12-820472-6.00041-4 · Cited by 256
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Waldron-Lynch, M., Eng-Wong, J., Kirk, S., & Cortés, J. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.021 · Cited by 275
Self-citationLuen, S. J., Salgado, R., Fox, S., Savas, P., Eng-Wong, J., Clark, E., Kiermaier, A., Swain, S. M., Baselga, J., Michiels, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30631-3 · Cited by 278
Self-citationProgress in adjuvant systemic therapy for breast cancer
Pondé, N. F., Zardavas, D., & Piccart, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0089-9 · Cited by 281
Renfro, L. A., & Sargent, D. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw413 · Cited by 271
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Gobbini, E., Ezzalfani, M., Dieras, V., Bachelot, T., Brain, E., Debled, M., Jacot, W., Mouret-Reynier, M. A., Goncalves, A., Dalenc, F., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.015 · Cited by 276
Self-citationSwain, S. M., Ewer, M. S., Viale, G., Delaloge, S., Ferrero, J.-M., Verrill, M., Colomer, R., Vieira, C., Werner, T. L., Douthwaite, H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx773 · Cited by 244
Self-citationKundu, M., Butti, R., Panda, V. K., Malhotra, D., Das, S., Mitra, T., Kapse, P., Gosavi, S. W., & Kundu, G. C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01990-4 · Cited by 250
Polytherapy and Targeted Cancer Drug Resistance
Chatterjee, N., & Bivona, T. G. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.003 · Cited by 270
Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives
Wang, J., & Wu, S.-G. (2023) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s432526 · Cited by 232
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
Broyles, A. D., Banerji, A., Barmettler, S., Biggs, C. M., Blumenthal, K., Brennan, P. J., Breslow, R. G., Brockow, K., Buchheit, K. M., Cahill, K. N., et al. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.08.006 · Cited by 235
Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M. S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.001 · Cited by 240
Treatment strategies for breast cancer brain metastases
Bailleux, C., Eberst, L., & Bachelot, T. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01175-y · Cited by 233
Understanding breast cancer – The long and winding road
Lukong, K. E. (2017) · BBA Clinical · doi:10.1016/j.bbacli.2017.01.001 · Cited by 232
Haen, S. P., Löffler, M. W., Rammensee, H.-G., & Brossart, P. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0387-x · Cited by 222
Curigliano, G., Mueller, V., Borges, V., Hamilton, E., Hurvitz, S., Loi, S., Murthy, R., Okines, A., Paplomata, E., Cameron, D., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.005 · Cited by 217
Novel HER2–targeted therapies for HER2–positive metastatic breast cancer
Kunte, S., Abraham, J., & Montero, A. J. (2020) · Cancer · doi:10.1002/cncr.33102 · Cited by 214
Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Chamberlain, M. C., Baik, C. S., Gadi, V. K., Bhatia, S., & Chow, L. Q. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now197 · Cited by 223
Rimawi, M., Ferrero, J.-M., de la Haba-Rodriguez, J., Poole, C., De Placido, S., Osborne, C. K., Hegg, R., Easton, V., Wohlfarth, C., Arpino, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7863 · Cited by 217
Self-citationCauses of death after breast cancer diagnosis: A US population‐based analysis
Afifi, A. M., Saad, A. M., Al‐Husseini, M. J., Elmehrath, A. O., Northfelt, D. W., & Sonbol, M. B. (2020) · Cancer · doi:10.1002/cncr.32648 · Cited by 210
Update on Metastatic Gastric and Esophageal Cancers
Shah, M. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1799 · Cited by 213
Enhancing global access to cancer medicines
Cortes, J., Perez‐García, J. M., Llombart‐Cussac, A., Curigliano, G., El Saghir, N. S., Cardoso, F., Barrios, C. H., Wagle, S., Roman, J., Harbeck, N., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21597 · Cited by 203
Self-citationChaganty, B. K. R., Qiu, S., Gest, A., Lu, Y., Ivan, C., Calin, G. A., Weiner, L. M., & Fan, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.009 · Cited by 209
Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography
Tan, D. S. W., Mok, T. S. K., & Rebbeck, T. R. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0096 · Cited by 202
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Friedlaender, A., Subbiah, V., Russo, A., Banna, G. L., Malapelle, U., Rolfo, C., & Addeo, A. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00558-1 · Cited by 193
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 200
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
de Melo Gagliato, D., Leonardo Fontes Jardim, D., Marchesi, M. S. P., & Hortobagyi, G. N. (2016) · Oncotarget · doi:10.18632/oncotarget.7043 · Cited by 198
Horisawa, N., Adachi, Y., Takatsuka, D., Nozawa, K., Endo, Y., Ozaki, Y., Sugino, K., Kataoka, A., Kotani, H., Yoshimura, A., et al. (2022) · Breast Cancer · doi:10.1007/s12282-021-01303-3 · Cited by 196
Nami, B., Maadi, H., & Wang, Z. (2018) · Cancers · doi:10.3390/cancers10100342 · Cited by 190
Deluche, E., Antoine, A., Bachelot, T., Lardy-Cleaud, A., Dieras, V., Brain, E., Debled, M., Jacot, W., Mouret-Reynier, M. A., Goncalves, A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.016 · Cited by 186
Self-citationMendes, D., Alves, C., Afonso, N., Cardoso, F., Passos-Coelho, J. L., Costa, L., Andrade, S., & Batel-Marques, F. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0648-2 · Cited by 187
Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed
den Brok, W. D., Speers, C. H., Gondara, L., Baxter, E., Tyldesley, S. K., & Lohrisch, C. A. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4080-9 · Cited by 188
Metadata
- Authors
- Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., Clark, E., Ross, G., Benyunes, M. C., & Cortés, J.
- Affiliations
- MedStar Washington Hospital Center (US)
- Asan Medical Center (KR)
- National Cancer Center (KR)
- Institute of Oncology NN Petrov (RU)
- Hospital Universitario 12 De Octubre (ES)
- Centre Antoine Lacassagne (FR)
- University Hospital Heidelberg (DE)
- Roche (United Kingdom) (GB)
- Genentech (US)
- Vall d'Hebron Hospital Universitari (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-19
- Volume
- 372
- Issue
- 8
- Pages
- 724-734
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5584549
- OpenAlex
- W2137228442
- Cited by
- 2,164
- References
- 26
- Citations by year
- 2026: 138 · 2025: 150 · 2024: 157 · 2023: 197 · 2022: 191 · 2021: 212 · 2020: 206 · 2019: 217 · 2018: 202 · 2017: 207 · 2016: 197 · 2015: 87
- FWCI
- 100.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Genentech
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- pertuzumab, trastuzumab, docetaxel, HER2-positive breast cancer, metastatic breast cancer, overall survival, progression-free survival, duration of response, cardiac safety, HER2-targeted therapy, first-line chemotherapy
- MeSH terms
- Trastuzumab, Docetaxel, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Infusions, Intravenous, Middle Aged, Neoplasm Metastasis, Survival Analysis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.